Pippa Anderson, MSc
Senior Principal, Health Economics and Outcomes Research at IMS in London, with experience is in qualitative research relating to health care and health economics, measurement and valuation of health, and in the communication of value evidence to health care decision makers through the medium of the Value Dossier - the crucial end product of outcomes research programmes.
Xavier Badia, MD, MPH, PhD
Senior Principal, HEOR of Health Outcomes Research Europe, a unit of IMS, in Spain, with extensive public sector research experience in outcomes research, patient reported outcomes (PROs), effectiveness and cost-effectiveness evaluations.
David S. Battleman, MD, MSc, MBA
Principal with over 15 years experience in the life sciences and has worked in a variety of settings, including healthcare consulting, the pharmaceutical industry, as well as in academia.
Marc Benoff, MBA
Vice President and Practice Leader Pricing and Market Access, Americas. He has extensive experience helping clients better understand, develop, and evaluate global pricing and market access strategies for new and existing products.
Karin Berger
Principal, Health Economics and Outcomes Research at IMS in Germany, with extensive experience in health outcomes research, health economic evaluation and modelling studies.
Annie Chicoye
Senior Principal at IMS Health in France. She has a strong background in Health Economics, health technology assessment and public health and industrial policies.
Laurence Fong
Principal, Pricing and Market Access at IMS Australia with extensive experience in leading and managing economic and public affairs in the pharmaceutical and health industry.
Frank-Ulrich Fricke, PhD
Principal, Health Economics and Outcomes Research at IMS in Germany, with a particular focus on health economic evaluations (cost analysis, economic modeling, cost effectiveness analysis), market access strategies and health policy.
David Grant, MBA
Senior Principal, Health Economics and Outcomes Research at IMS in the UK, specialises in providing strategic advice, particularly for products in early development and has led client projects relating to burden-of-illness reviews, reimbursement and market access environmental analysis.
Claude Le Pen, PhD
Professor of Economics at Paris-Dauphine University and member of the Strategic Committee of IMS France. He has experience of being member of various committees, including the French Transparency Commission.
Adam Lloyd, MPhil
Senior Principal, Health Economics and Outcomes Research at IMS in London, specialist in economic analysis and economic modelling with extensive experience of leading economic evaluations of products in clinical development and post-launch, decision-analytic and Markov modelling and in using health economics in reimbursement and marketing activities in continental Europe.
Olaf Pirk, MD, PhD
Principal, Health Economics and Outcomes Research at IMS in Germany, with a particular focus on economics evaluations, market access strategics and health policy.
Jon Resnick, MBA
Vice President and Practice Leader Pricing and Market Access, EMEA. His experience combines a unique blend of public policy and industry expertise to advise pharmaceutical and biotech companies on a wide range of strategy, pricing and reimbursement issues.
Jonothan C. Tierce, CPhil
General Manager and Center of Excellence Leader Global HEOR with nearly 25 years of experience in health economics research and consulting for the pharmaceutical, medical device and diagnostics industries.